GlaxoSmithKline plc has hit the acquisition trail to buy Sierra Oncology, Inc. and bolster its late-stage cancer pipeline with the promising myelofibrosis drug momelotinib.
Another New Home For Momelotinib As GSK Buys Sierra
Drug Major Pays $1.9bn To Boost Blood Cancer Pipeline
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
More from Deals
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.